SEC Tracker
Get the app
CODX · XBRL financial data

Co-Diagnostics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CODX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue from contracts with customers2,4573,555*4682,657641149*50163145264*146166
Cost of revenue2562,968*235212297255*223226142*19445
Gross profit2,201587*2332,445344(106)*29131119122*(48)121
Research and development5,7896,179*5,6805,6134,8804,807*4,8704,6874,4815,099*5,9344,152
General and administrative3,1484,404*2,9193,1324,2875,819*2,7732,6001,8161,869*2,5031,501
Total operating expenses11,13712,413*10,49310,12510,57911,801*8,5818,1897,13326,663*9,1616,322
Operating income (loss)(8,936)(11,825)*(10,259)(7,680)(10,235)(11,907)*(8,552)(8,058)(7,014)(26,542)*(9,208)(6,201)
Income tax expense (benefit)(2,114)3,834*232122(8)*1212(1,167)(474)*119
Net income (loss)(5,982)(14,676)*(9,312)(7,599)(9,696)(11,031)*(7,533)(7,730)(5,887)(25,746)*(9,140)(6,284)
Earnings per share, basic USD per share(0.20)(0.50)*(0.31)(0.25)(0.32)(0.36)*(0.24)(0.23)(0.16)—(4.06)(1.46)
Earnings per share, diluted USD per share(0.20)(0.50)*(0.31)(0.25)(0.32)(0.36)*(0.24)(0.23)(0.16)—(4.06)(1.46)
Weighted average shares, basic thousands of shares29,36129,454*29,84330,12530,49430,872*32,04933,10837,891—2,2534,310
Weighted average shares, diluted thousands of shares29,36129,454*29,84330,12530,49430,872*32,04933,10837,891—2,2534,310
  • † Share count changed about 1/17 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (CODX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents10,24014,91723,09913,85910,7982,9371,90311,11511,44411,8858,2313,650
Marketable securities53,18943,63226,86431,02126,86526,81119,5762,248————
Accounts receivable807304435552178133136211561908252
Inventory4,5201,6651,5501,4641,2661,0731,0831,0851,090992846842
Prepaid and other current assets1,2901,5971,7501,3249971,3391,133649542582623649
Total current assets71,31162,14153,69948,21940,10332,29223,83115,30714,05513,6939,7825,192
Property and equipment, net2,8083,0363,1833,0542,9842,7612,5942,6732,4852,2722,1591,975
Right-of-use asset3,0322,9672,7592,5472,3332,1151,8931,6681,4401,2072,0031,769
Total assets108,68295,32186,67180,70172,38164,00055,14946,46644,74124,74321,50016,591
Accounts payable1,4161,4822,0281,8632,1763,2942,7131,6351,4581,8782,0181,078
Accrued liabilities1,8272,1731,3251,5051,8262,5621,6111,0081,2058651,365899
Total current liabilities5,0985,7485,2705,3055,7987,3165,3773,7113,6933,5404,2852,863
Lease liability, non-current2,2502,1521,9311,7041,4721,2371,0288797285741,1731,015
Total liabilities9,1929,3078,3188,3048,5979,6887,2295,3274,9134,1145,4573,878
Retained earnings (accumulated deficit)19,2754,598(4,714)(12,313)(22,010)(33,041)(40,574)(48,304)(54,191)(80,374)(89,514)(95,797)
Total stockholders' equity99,49086,01478,35372,39863,78454,31247,92141,13839,82820,62916,04212,712
Total liabilities and equity108,68295,32186,67180,70172,38164,00055,14946,46644,74124,74321,50016,591
Common shares outstanding (cover page) thousands of shares30,58131,26031,27831,91131,93033,57333,71338,52460,8933,6023,6026,252
  • † Share count changed about 1/17 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (CODX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025†Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(5,982)(14,676)*(9,312)(7,599)(9,696)(11,031)*(7,533)(7,730)(5,887)(25,746)*(9,140)(6,284)
Stock-based compensation2,172*1,826*1,5711,500*1,046*1,318*875580*501*292*219214*
Depreciation and amortization296*313*331338*351*357*280291*267*———
Net cash from operating activities(6,594)*(4,779)*(8,490)(5,204)*(7,230)*(8,231)*(8,745)(8,288)*(5,905)*(6,199)*(7,846)(7,153)*
Purchases of property and equipment237*465*40299*174*73*92401*75*132*14218*
Net cash from investing activities3,170*9,615*16,673(4,036)*4,168*266*7,35717,071*2,175*(329)*(142)(168)*
Share repurchases166*160*——————————
Net cash from financing activities(166)*(160)*———year only355429*4,058*6,969*4,3352,740*
Net change in cash(3,591)*4,677*8,182(9,240)*(3,061)*(7,861)*(1,034)9,212*329*441*(3,654)(4,581)*
  • † Share count changed about 1/17 in the period ending 2025-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Co-Diagnostics3,650166(7,153)*6.3M0.5 quarters 10-QJun 30, 2026
Lifeward9,4486,623(6,005)*2.8M1.6 quarters 10-QJun 30, 2026
Mountain Crest Acquisition Corp. V18not reported(79)*2.9M0.2 quarters 10-QJun 30, 2026
Guided Therapeutics120(319)*96.5M0.0 quarters 10-QJun 30, 2026
Medinotec2,5843,201108*11.8M— 10-QAug 31, 2026
Nexgel1,7063,686(2,197)*9.7M0.8 quarters 10-QJun 30, 2026
Lyra Therapeutics15,8937*(6,066)*1.8M2.6 quarters 10-KDec 31, 2025
Intelligent Bio Solutions3,9921,146*(3,182)*3.0M1.3 quarters 10-KJun 30, 2026
PAVmed3,78433(2,663)*8.0M1.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.